UCSF PANC Cyst Registry

Recruiting

• Conditions: Intraductal Papillary Mucinous Neoplasm; Pancreatic Intraductal Papillary Mucinous Neoplasm; Pancreatic Ductal Adenocarcinoma; Mucinous Cyst; Pancreatic Cyst; Pancreatic Neoplasms; Pancreatic Cancer; Pancreatic Diseases
• Interventions: Other: Survey

• Registration Number: NCT04291651
• Lead Sponsor: University of California, San Francisco

Brief Summary

Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. This presents a clinical challenge to prevent unnecessary resection of indolent disease, with associated risks of infections, bleeding, diabetes, and costly disability. Unfortunately, there is little information on the epidemiology and natural history of pancreatic cysts to help guide management.

Detailed Description

This study develops a large, prospectively managed, electronic, patient-directed pancreatic cyst registry based at UCSF. The UCSF Pancreatic Cystic Lesions Registry (PANC Cyst) will facilitate work to improve clinical care and understanding of pancreatic cysts by prospective follow-up of patients with cystic lesions, especially the diagnostically challenging small cysts, to identify factors related to cyst formation and progression to malignancy. Longitudinal data capture that includes clinical outcomes will also enable us to more precisely define anatomic, radiographic and biomarker information that can be used to differentiate populations of patients for whom surgery is indicated, surveillance is warranted, or no further evaluation is necessary.

Study Timeline

• Study Start: 2019-10-08
• Study First Submitted: 2020-02-26
• Study First Submitted QC: 2020-02-27
• Study First Posted: 2020-03-02
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-27
• Last Update Posted: 2023-07-28
• Primary Completion: 2030-01-01
• Study Completion: 2030-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 4000

Inclusion Criteria

• The inclusion criteria for this study are intentionally broad. Eligible patients for prospective enrollment will include
• Adults ≥ 30 years of age
• Have a radiographic or endoscopic diagnosis of at least one pancreatic cysts regardless of treatment status,
• No history of pancreatic cancer,
• Can speak and read English,
• Have access to a computer or mobile device (~95% of U.S. population); and
• Are able to complete an electronic informed consent.

Read More

Exclusion Criteria

• Patients who don't speak English,
• Don't have access to a computer or mobile device; or
• Patients who have a cancer diagnosis.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Prospective	Survey	The prospectively enrolled patients in this study are the primary population of interest.

Primary Outcome Measures

Name	Time	Method
Indolency	1-10 years	If a patient with a pancreatic cyst experiences no or minimal change in size, and no development of worrisome or high-risk stigmata (Tanaka 2017), this will be considered to be an indolent lesion. Most patients will fall under this category.
Cancer	1-10 years	While not the primary outcome measure, the development of cancer from a pancreatic cyst is a critically important study endpoint, which the investigators do not expect to be frequent occurrence.

Trial Locations

Locations (1)

University of California, San Francisco; 🇺🇸 San Francisco, California, United States